We provide an open access dataset for hybrid brain-computer interfaces (BCIs) using electroencephalography (EEG) and near-infrared spectroscopy (NIRS). For this, we con-ducted two BCI experiments (left vs. right hand motor imagery; mental arithmetic vs. resting state). The dataset was validated using baseline signal analysis methods, with which classification performance was evaluated for each modality and a combination of both modalities. As already shown in previous literature, the capability of discriminating different mental states can be en-hanced by using a hybrid approach, when comparing to single modality analyses. This makes the provided data highly suitable for hybrid BCI investigations. Since our open access dataset also comprises motion artifacts and physiological data, we expect that it can be used in a wide range of future validation approaches in multimodal BCI research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/TNSRE.2016.2628057 | DOI Listing |
JAMA Netw Open
January 2025
Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
Importance: Clinical trials are vital for advancing cancer treatments and improving patient outcomes. Understanding the factors that influence participants' decision-making is critical for enhancing trial recruitment.
Objective: To evaluate the attitudes of patients with cancer and their relatives toward clinical trial participation, identifying key barriers and motivators that affect their willingness to engage in such trials.
Pharmaceut Med
January 2025
Pharmaceutical Medicine, Dover Heights, Sydney, NSW, Australia.
Pharmaceutical medicine professionals have to face many ethical problems during the entire life span of new medicines extending from animal studies to broad clinical practice. The primary aim of the general ethical principles governing research conducted in humans is to diminish the physical and psychological burdens of the participants in human drug studies but overlooks many additional social and ethical problems faced by medicine developers. These arise mainly at the interface connecting the profit-oriented pharmaceutical industry and the healthcare-centered medical profession cooperating in medicines development.
View Article and Find Full Text PDFPatient
January 2025
Pfizer, New York City, NY, USA.
Using patient preference information (PPI) to incorporate patient voices into the drug development lifecycle can help align therapies with the needs and values of patients. However, several barriers have limited the use of PPI, including a lack of clarity on its use by decision-makers, a need for greater decision-maker trust in PPI, and a lack of time, budgets, and access to specialist expertise. The value proposition for PPI could be enhanced by making it FAIR: Findable, Accessible, Interoperable, and Reusable.
View Article and Find Full Text PDFPatient
January 2025
Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Background: In the context of injectable biologic products approved or in development for chronic spontaneous urticaria (CSU), it is important to capture which treatment attributes matter most to patient and what trade-offs patients are willing to make.
Objectives: The CHOICE-CSU study aimed to quantify patient preferences toward injectable treatment attributes among patients with CSU, inadequately controlled by H1-antihistamines.
Methods: This was a two-phase cross-sectional patient preference study in adult patients with a diagnosis of CSU, inadequately controlled by H1-antihistamines.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!